Suppressing the immune system to reduce brain inflammation, a known contributor to Parkinson’s disease progression, may offer a promising new strategy for slowing the disease, early trial results suggest. Specifically, azathioprine, a commonly used drug that suppresses immune activity, reduced motor symptoms and improved cognitive function in people…
Crexont, an extended-release oral formulation of carbidopa and levodopa, significantly improved sleep quality in people with Parkinson’s disease. That’s according to data based on additional analysis of the Phase 3 RISE-PD trial (NCT03670953). The results were detailed in a presentation, “Conversion to CREXONT in…
U.S. researchers have identified a novel way to block a protein known as DLK, or dual leucine-zipper kinase, that may offer a promising strategy to protect neurons from degeneration — which, the team notes, could pave the way for safer and more precise treatments for neurodegenerative conditions like Parkinson’s…
Pretzel Therapeutics has launched a Phase 1 clinical trial to study PX578, a therapy designed to boost the function of mitochondria, the cell’s energy-producing powerhouses, and address conditions caused by faulty energy production. These include rare genetic conditions and neurodegenerative disorders like Parkinson’s and Alzheimer’s. The…
When used as a solo therapy, solengepras (CVN424) — an oral treatment being developed by Cerevance — was seen to lessen both functional and nonmotor symptoms in people with early, untreated Parkinson’s disease. That’s according to top-line results from the Phase 2 ASCEND trial (NCT06006247), which…
Medications commonly used to treat conditions such as high blood pressure, high cholesterol, and pain may delay Parkinson’s disease onset, according to a U.S. study. Analyses found that anti-hypertensives such as adrenergic blockers, cholesterol-lowering statins, and non-steroidal anti-inflammatory drugs (NSAIDs) were strongly associated with later onset disease. In contrast,…
A new positron emission tomography (PET) radiotracer can accurately visualize inflammation within the healthy human brain, a first-in-human study found. By using a marker that binds to COX-2, a key enzyme associated with brain inflammation or neuroinflammation, researchers were able to quantify low levels of this enzyme in healthy individuals.
Irlab Therapeutics is moving its oral candidate, IRL757, into a Phase 1b clinical study to assess its safety and explore early signs of efficacy in treating apathy in people with Parkinson’s disease. Patient enrollment is expected to begin in the second half of 2025. Financial support for the trial…
The Michael J. Fox Foundation (MJFF) has brought together top experts from around the world to speed up research on five lesser-known biological targets in Parkinson’s disease in an effort to identify promising treatment opportunities. Seven more will be explored in a future phase. This effort is part…
Get regular updates to your inbox.
